Spots Global Cancer Trial Database for belantamab mafodotin
Every month we try and update this database with for belantamab mafodotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Corneal Toxicity in Patients Treated by Belantamab Mafodotin | NCT05887206 | Myeloma Multipl... | Collection of d... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma | NCT03763370 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | NCT04680468 | Myeloma | Belantamab mafo... | 18 Years - | University of Pennsylvania | |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | NCT04680468 | Myeloma | Belantamab mafo... | 18 Years - | University of Pennsylvania | |
| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | NCT05208307 | Plasma Cell Mye... | Belantamab Mafo... Dexamethasone Pomalidomide | 18 Years - | Emory University | |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | NCT05060627 | Relapsed Multip... | Belantamab mafo... Carfilzomib Dexamethasone | 18 Years - | PETHEMA Foundation | |
| Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT05986682 | Multiple Myelom... | Blenrep | 18 Years - 89 Years | Duke University | |
| A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | NCT05556798 | Multiple Myelom... | Belantamab Mafo... Nirogacestat Pomalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | NCT05847569 | Recurrent Multi... Refractory Mult... | Belantamab Mafo... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Positron Emissi... | 18 Years - | Mayo Clinic | |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | NCT05789303 | Multiple Myelom... Relapse Multipl... | Belantamab mafo... Carfilzomib Pomalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | NCT05493618 | Multiple Myelom... | Pembrolizumab Belantamab mafo... Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| Corneal Toxicity in Patients Treated by Belantamab Mafodotin | NCT05887206 | Myeloma Multipl... | Collection of d... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | NCT04892264 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... | Belantamab Mafo... Daratumumab Dexamethasone Lenalidomide Quality-of-Life... Biospecimen Col... Skeletal Survey... Low Dose Comput... Bone Marrow Asp... Bone Marrow Bio... | 18 Years - | Mayo Clinic | |
| A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | NCT04177823 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | NCT04676360 | Relapsed Plasma... Refractory Plas... Anaplastic Lymp... | Belantamab Mafo... | 18 Years - | Massachusetts General Hospital | |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | NCT05064358 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | NCT05065047 | Multiple Myelom... | Belantamab mafo... | 18 Years - | M.D. Anderson Cancer Center | |
| Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | NCT05091372 | Myeloma Multipl... | Belantamab mafo... Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | NCT04808037 | Multiple Myelom... | Belantamab mafo... | 18 Years - | Hellenic Society of Hematology | |
| Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | NCT04802356 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone Autologous stem... | 18 Years - | PETHEMA Foundation | |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | NCT04617925 | AL Amyloidosis | Belantamab mafo... | 18 Years - | Stichting European Myeloma Network | |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | NCT05714839 | Multiple Myelom... | Bela Belamaf Lenalidomide Dexamethasone Standard of Car... | 18 Years - | GlaxoSmithKline | |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | NCT05714839 | Multiple Myelom... | Bela Belamaf Lenalidomide Dexamethasone Standard of Car... | 18 Years - | GlaxoSmithKline | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function | NCT04398680 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Corneal Findings in Patients Treated With Belantamab Mafodotin | NCT05833737 | Multiple Myelom... Corneal Disease... Corneal Cyst | Belantamab mafo... | 18 Years - | Medical University of Vienna | |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT05117008 | Refractory Mult... Relapse Multipl... | Belantamab mafo... | 18 Years - | Medical College of Wisconsin | |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | NCT05853965 | Multiple Myelom... Multiple Myelom... | Belantamab mafo... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | NCT05789303 | Multiple Myelom... Relapse Multipl... | Belantamab mafo... Carfilzomib Pomalidomide Dexamethasone | 18 Years - | University of Chicago | |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | NCT04617925 | AL Amyloidosis | Belantamab mafo... | 18 Years - | Stichting European Myeloma Network | |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | NCT05714839 | Multiple Myelom... | Bela Belamaf Lenalidomide Dexamethasone Standard of Car... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma | NCT03763370 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | NCT05853965 | Multiple Myelom... Multiple Myelom... | Belantamab mafo... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | NCT03848845 | Multiple Myelom... | belantamab mafo... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
